logo
Plus   Neg
Share
Email

Boston Scientific Guides FY20 Adj. EPS In Line With Estimates - Quick Facts

While reporting financial results for the fourth quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) initiated its adjusted earnings and revenue growth guidance for the full-year 2020 and for the first quarter of fiscal 2020.

For fiscal 2020, the company now projects earnings in a range of $0.95 to $1.00 per share and adjusted earnings in a range of $1.74 to $1.79 per share on revenue growth in a range of about 10 to 12 percent and organic revenue growth of about 6.5 to 8.5 percent.

Full year organic guidance excludes the impact of foreign currency fluctuations and contribution of approximately 350 basis points from the acquisitions of Vertiflex and BTG, as well as the impact of the divestiture of our global embolic microspheres portfolio as part of the acquisition of BTG.

On average, analysts polled by Thomson Reuters expect earnings of $1.78 per share on revenue growth of 12.1 percent to $12.05 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company estimates earnings in a range of $0.16 to $0.19 per share and adjusted earnings, excluding certain charges (credits), in a range of $0.37 to $0.40 per share. It anticipates revenue growth of about 10 to 12 percent and organic revenue growth of about 5 to 7 percent.

Analysts expect earnings of $0.41 per share on revenue growth of 14.5 percent to $2.85 billion for the quarter.

"We're confident that we have the pipeline, leadership team and focused execution to deliver on our goals to address unmet clinical needs and work to improve the lives of millions of patients," said Mike Mahoney, chairman and chief executive officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT